Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Data Highlights Benefits, Risks of Obesity Surgery

Executive Summary

Obesity has become an epidemic, with 30% of the U.S. population obese and an additional 35% overweight, including children and adolescents. Bariatric surgical procedures have skyrocketed in recent years, with hospital costs exceeding $1.2 billion, and good success rates. However, for certain groups, such as patients over 65, the risks of bariatric surgery may outweigh the benefits. Much needs to be done to address this troubling and growing public health problem.

You may also be interested in...



Hot Topics in Bariatrics

At this year's American Society for Bariatric Surgery (ASBS) meeting, held in San Diego in June, innovation was on display as researchers and device manufacturers showcased several new approaches and technologies for bariatric surgery.

Hot Topics in Bariatrics

At this year's American Society for Bariatric Surgery (ASBS) meeting, held in San Diego in June, innovation was on display as researchers and device manufacturers showcased several new approaches and technologies for bariatric surgery.

Device Financing in 2006: Closing the Gap with Biopharma

While device companies didn't raise as much in venture capital over the course of 2006 as their biopharma counterparts did, they did close the gap considerably.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel